Posts Tagged: "acacia research"

At the very beginning of the program Siegel, during his opening remarks, said: “At Acacia we are not in the litigation business, we are in the licensing business.” I know that many will shrug or laugh at the comment, but from what I know about Acacia if you care to dig underneath the surface and listen past the sound byte it is true. Siegel explained that there are real costs and real risks associated with litigation, so doing business together and licensing is always a preferable strategy. Of course, Siegel pointed out that there is still a reluctance by many entities to pay for intellectual property. Siegel is exactly correct. There are many companies, large companies who themselves are owners of very large patent portfolios, who are reluctant to pay for intellectual property rights even though they infringe. Somewhere along the way it seems that the narrative got away from the innovator and has been turned on its head.

Siegel: “I think this effort to destroy the value of intellectual property is a bigger wet towel on innovation. When startup companies, after they get their angel investing, go out to try and raise funds on round Bs and round Cs, one of the things that investors look at is whether or not that company has an innovation that is different and protectable so that the investors know that number one there is something in there that’s protectable so that they can protect their investment. And when companies, small companies that make the investment into intellectual property portfolio development it sends a signal, two signals. It sends a signal that, number one, they’re progressive enough and smart enough to think about protecting their innovation. And, number two, it provides collateral for the investments that the investors are making into the company. So if the company were to not be successful in its business, they would have this asset of an IP portfolio sitting there that could still be sold or otherwise monetized to help the investors recoup their investments.”

Pitney Bowes and IBM to Collaborate on Hybrid Cloud Location Services ***** Patent Lawsuits Filed Over 3D Cinema Projection Technology ***** Microsoft and Dell Sign Patent Licensing Agreement ***** Tessera Technologies Ends Litigation Against Qualcomm ***** More Patents Tossed from Remote Control Patent Dispute

The month of January started off quite busy, which in all likelihood was as the result of deals and announcements either held over or that simply couldn’t get done in the run up to closing out the year. There was a noticeable lull in news and announcements. This month some of the highlights included (1) an exclusive option to license drugs targeting Parkinson’s disease; (2) potential patent problems on the horizon for Facebook; (3) additional settlements in the Forest Laboratory’s BYSTOLIC® patent litigation; (4) the inevitable news from Acacia Research; plus more.

Paul Ryan is a more common name than you might think. In the world of politics when one speaks of “Paul Ryan” they are talking about the Republican Congressman from Wisconsin who was Mitt Romney’s running-mate and would-have-been Vice President. But in the intellectual property world, particularly the patent litigation world, the name “Paul Ryan” refers to the CEO of Acacia Research Technologies. It is the later Paul Ryan that went on the record with me to discuss Acacia, patent enforcement, how large companies who are infringers disregard innovative independent inventors and more.

Acacia announced that the Company’s Board of Directors has authorized a program for repurchasing shares of the Company’s outstanding common stock. The stock repurchase program will be put into effect immediately. Under the stock repurchase program, the Company is authorized to purchase in the aggregate up to $100 million of its common stock through the period ending May 15, 2013. Meanwhile, HTC settles with Apple and more.

On November 8, 2012, Mylan Inc. (Nasdaq: MYL) announced that it, along with Famy Care Ltd., has entered into a settlement agreement with Janssen Pharmaceuticals Inc. that will resolve patent litigation related to Ortho Tri-Cyclen Lo® Tablets, which are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Also on November 8, Research Affiliates, LLC and WisdomTree Investments, Inc. (NASDAQ: WETF) announced that Research Affiliates will withdraw its patent infringement lawsuit brought against WisdomTree and pay WisdomTree $700,000. On October 31, 2012, Acacia Research Corporation (Nasdaq:ACTG) announced that its subsidiaries settled patent litigation with Medtronic and Comcast Cable in unrelated cases.

One of the newer prior art research studies currently underway at Article One Partners is one that relates to U.S. Patent No. 6,332,158, which relates to a system that assists user’s in selecting desired domains. This study is of particular interest because the patent in question is owned by a subsidiary of Acacia Research Corporation, which is one of the largest and most powerful of the patent assertion entities (PAE) in the industry today. The technology in question in the Acacia owned patent is a domain name lookup system and associated method. In the method a domain name query is sent from a resolver process when the user wishes to obtain information. If the domain name exists, the domain name server provides the corresponding machine address back to the user’s computer. However, when the domain name query uses a non-existent domain name then a machine address for a computer that executes a domain recommendation engine is provided. The domain recommendation engine assists the user in locating a desired domain name.

This deal will give GSK exclusive rights to BENLYSTA, which is a human monoclonal antibody that inhibits B-cell activating factor (BAFF) approved for treatment of systemic lupus erythematosus. It is believed that BENLYSTA has blockbuster potential. According to Human Genome Sciences, the principle patents covering BENLYSTA will generally expire between 2016 and 2023 in the United States and between 2016 and 2021 in the rest of the world. For 2011 sales of BENYLYSTA were approximately $52 million, but there is great optimism that the drug will become a blockbuster as it continues to gain market share and as it may ultimately be approved for treatment of other autoimmune diseases.

Merck and AstraZeneca Agree to Amend Partnership – Theradiag Acquires Innovative MicroRNA Technology Platform – 8×8 Sells Patent Family – MPEG LA Announces Call for Patents Essential HEVC – International Rectifier Enters Into Patent License Agreement – Acacia Subsidiary Acquires 156 U.S. and International Patents – Acacia Subsidiary Acquires Patents for X-Ray Powder Diffraction.

The types of returns promised to investors and the types of benefits offered to participants are also quite different from garden-variety non-practicing entities, as are some of the tactics used in organizing the entities and in asserting the patents. Finally, the scale itself is simply mind-boggling. Mass aggregators operate on a scale and at a level of sophistication and complexity that would have been unimaginable a decade ago. They have taken the prototype strategies pioneered by a prior generation of non-practicing entities and changed them into some of the cleverest strategies yet seen in the intellectual property rights field.

Acacia has long been considered by many to be the mother of all patent trolls. But are they really a patent troll? The term “patent troll” is one that is nearly impossible to define given the reality that one man’s patent troll is another man’s innovator who just chooses to license. Increasingly, however, the true bad actors in the non-practicing entity community are engaging in what the Federal Circuit has called extortion-like behavior. Is Acacia Research one of those patent trolls that engages in mafioso tactics, or are they a godsend to inventors and small businesses who otherwise couldn’t monetize their patent portfolios?

In this edition of News, Notes & Announcements, websites engaged in the sale of counterfeit merchandise were ordered seized as part of a joint investigation coordinated between the Department of Justice and ICE. Additionally, there will be an event celebrating the 30th Anniversary of passage of the Bayh-Dole Act in Washington, DC on Wednesday morning; the USPTO will hold a roundtable on Friday, December 3, 2010 to discuss trademark prosecution best practices; FIRST, the company founded by Dean Kamen, received a 5 year contract from NASA to provide support for hands-on robotics competitions aimed at inspiring our youth to pursue science and technology; ITT launches an innovative new graduate program that combines engineering, design and intellectual property; the mother of all patent trolls is back at it both in terms of licensing and in terms of acquiring more patents; and patented software that makes it possible to find plagiarized code is released.